Genetic Testing Cogentech - Overview

Cogentech provides physicians, laboratories, and hospitals with diagnostic services for hereditary cancers (cancer risk) and for personalized medicine (therapy).

The excellence of our diagnostic services is based on the expertise of highly qualified staff, continuous investment in training and innovation, strict adherence to high quality standards and a strong commitment to delivering the best possible diagnostic service.

1/6

2/6

3/6

4/6

5/6

6/6

❮ ❯

The CGT Lab, based in Milan, has worked initially as a research group and, since 2011 within Cogentech SB Srl as a diagnostic services laboratory, in analyzing susceptibility variants for hereditary cancers, providing test results to more than 30,000 patients. We continuously innovate and improve our portfolio through close interaction with our holding company, the cancer research institute IFOM ETS, and with our clinical clients and collaborators.

From 2025, Cogentech’s diagnostic offering has been further expanded: the IGU laboratory (Integrated Genomic Unit), located in Catania, has also been authorized to provide diagnostic services, enabling Cogentech to make its services accessible to an even broader audience.

For our services, we use both proprietary solutions (OncoPan^®, OncoPed^®, OncoHRD^®, Sanger Sequencing) and commercial kits (MLPA, MS-MLPA, WES, WGS) to deliver the best diagnostic solutions.

We currently serve major public hospitals and several private facilities in the Lombardy region, and we have also started operations in Sicily.

Furthermore, Cogentech’s genetic testing laboratory, CGT Lab, is officially accredited by the Italian National Health Service and holds ISO 9001 certification as well as SIGUCERT certification issued by the Italian Society of Human Genetics.

CGT Lab, diagnostics service of Cogentech S.r.l. Società Benefit a Socio Unico, is accredited by ACCREDIA, the Italian national accreditation body, in accordance with the ISO 15189 standard. This accreditation demonstrates not only that the laboratory operates under a robust quality management system, but also that its staff possess the technical competence required to deliver reliable and valid results for the accredited tests.

The IGU laboratory is currently authorized to conduct diagnostic activities and, in 2025, achieved ISO 9001 certification for its diagnostic operations.

The company operates in the field of cancer molecular genetics, and its objective is to develop diagnostic tools for the identification and quantification of specific germline genomic patterns that predispose individuals to the risk of developing cancer. For this purpose, it has developed the proprietary tool OncoPan^®. In addition to diagnosing the presence of pathogenic variants in known genes associated with hereditary cancer syndromes, this tool can be used for population screening of hereditary–familial forms of breast/ovarian and colorectal cancer, in order to identify carriers of pathogenic germline variants in genes linked to these cancers, and to assess-through PRS (for breast cancer)-the overall genetic risk for this disease.

Cogentech’s values, as a Benefit Corporation, are reflected in its commitment to pursuing goals of common benefit, as established in its articles of association and certified in the annual "impact report."

We are a Benefit Corporation and, as such, we are committed to proposing solutions to problems with significant social impact, such as those related to cancer diagnosis. We operate in the market by offering innovative and original solutions that reflect our strong Benefit-driven mission to invest in research and development, as guided by our sole shareholder, IFOM ETS. We also provide diagnostic solutions for niche conditions that are often overlooked by large commercial companies (for example, pediatric cancers).

The differences between us and our competitors are mainly due to the company’s Benefit nature, but above all to its ownership structure, with the IFOM ETS Foundation as the sole shareholder and the charitable association AIRC, which controls it. This “virtuous circle” places Cogentech at its center: on one side, the company benefits from the innovation generated by IFOM’s research; on the other, it responds to the need to provide concrete solutions in the field of oncological diagnostics, meeting the expectations of both cancer patients and the general public, as embodied by AIRC.

Finally, it should be emphasized that the profits of Cogentech paid to its sole shareholder, IFOM, are, by statute, used by the latter to fund research.

We consider any complaints you may have as an important quality tool and a starting point for promoting continuous improvement actions in the services provided by Cogentech laboratories. For both CGT Lab and IGU, the relationship with the client represents a fundamental element, as does the ongoing commitment to improving the user experience and satisfaction.

You may submit any complaints by sending an email to the following addresses:
For CGT Lab (located in Lombardy): gtic-service[@]ifom.eu
For IGU (located in Sicily): diagnostic-igu[@]cogentech.it